Reference

Oxidative renal damage in pyelonephritic rats is ameliorated by montelukast, a selective leukotriene CysLT1 receptor antagonist

All Rights Reserved. Oxidative renal damage in pyelonephritic rats is ameliorated by montelukast, a selective leukotriene CysLT1 receptor antagonist. Tugtepe, Halil; Sener, Goeksel; Cetinel, Sule; Velioglu-Oeguenc, Ayliz; Yegen, Berrak C. (School of Medicine, Department of Pediatric Surgery, Marmara University, Istanbul, Turk.). European Journal of Pharmacology, 557(1), 69-75 (English) 2007 Elsevier B.V. CODEN: EJPHAZ. ISSN: 0014-2999. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) Urinary tract infections may induce severe inflammation, transient impairment in renal function and scar formation, ranging in severity from acute symptomatic pyelonephritis to chronic pyelonephritis, which have a potential to lead to renal failure and death. The present study aimed to investigate the possible protective effect of montelukast, a selective antagonist of cysteinyl leukotriene receptor 1 (leukotriene CysLT1), against Escherichia coli-induced oxidative injury and scarring in renal tissue. Wistar rats were injected 0.1 mL of E. coli (ATCC 25922 1010 cfu/mL) or saline into left renal medullae. Six rats were assigned as the sham group and were given 0.1 mL 0.In this article, certain chemicals are used. Some of their cas registry numbers are 70-18-8 and 158966-92-8 9% NaCl. Pyelonephritic rats were treated with either saline or montelukast immediately after surgery and at daily intervals. Twenty-four hours or one week after E. coli injection, rats were decapitated and the kidney samples were taken for histol. examn. or detn. of renal malondialdehyde, glutathione (GSH) levels, myeloperoxidase (MPO) activity, and collagen contents. Formation of reactive oxygen species in renal tissue samples was monitored by using chemiluminescence technique with luminol and lucigenin probes. Creatinine, blood urea nitrogen and lactate dehydrogenase (LDH) activity were measured in the serum samples. E. coli inoculation caused significant increases in malondialdehyde level, MPO activity, chemiluminescence levels and collagen content, while GSH level was decreased in the renal tissues (p < 0.05-0.001). On the other hand, serum TNF-alpha, LDH, blood urea nitrogen and serum creatinine levels were elevated in the pyelonephritic rats as compared to control group. Leukotriene CysLT1 receptor antagonist montelukast reversed all these biochem. indexes, as well as histopathol. alterations, that were induced by acute pyelonephritis. It seems likely that montelukast protects kidney tissue by inhibiting neutrophil infiltration, balancing oxidant-antioxidant status, and regulating the generation of inflammatory mediators suggesting a future role for leukotriene CysLT1 receptor antagonists in the treatment of pyelonephritis. .

Desloratadine in combination with montelukast suppresses the dermographometer challenge test papule, and is effective in the treatment of delayed pressure urticaria: a randomized, double-blind, placebo-controlled study

All Rights Reserved. Desloratadine in combination with montelukast suppresses the dermographometer challenge test papule, and is effective in the treatment of delayed pressure urticaria: a randomized, double-blind, placebo-controlled study. Nettis, E.; Colanardi, M. C.; Soccio, A. L.; Ferrannini, A.; Vacca, A. ( Department of Medical Clinic, Immunology and Infectious Diseases, Division of Allergy and Clinical Immunology, University of Bari Medical School, Bari I-70124, Italy). British Journal of Dermatology, 155(6), 1279-1282 (English) 2006 Blackwell Publishing Ltd. CODEN: BJDEAZ. ISSN: 0007-0963. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) Background Delayed pressure urticaria (DPU) comes under the heading of phys. urticaria. Characteristically itchy, tender or painful weals occur at sites of local pressure including the waistband, soles of the feet and palms of the hands. Lesion onset is typically 3-12 h after the application of pressure, and lesions may persist for more than 24 h.In this article, certain chemicals are used. Some of their cas registry numbers are 100643-71-8 and 158966-92-8 The treatment of DPU is often unsatisfactory. Objectives To det. the efficacy of desloratadine and montelukast in the treatment of DPU. Methods The study was conducted in 36 subjects affected by DPU. A challenge test with a dermographometer was administered to confirm the diagnosis. After diagnosis, patients were randomized to receive the following treatment once daily for 2 wk: (i) oral desloratadine 5 mg plus oral placebo; (ii) oral desloratadine 5 mg plus montelukast 10 mg; and (iii) oral placebo alone. Results At rechallenge, patients from the treatment groups (desloratadine plus montelukast group and desloratadine alone group) demonstrated a significant redn. in mean diam. of papules after 70 s of pressure compared with the placebo group (P < 0×05). Moreover, patients treated with desloratadine plus montelukast showed a significant redn. in mean diam. of papules at 70 s of pressure compared with those treated with desloratadine alone (P < 0×05). In addn., the combination was effective in improving clin. parameters (erythema, edema and pruritus, and no. of sep. urticarial episodes). Conclusions This study has demonstrated that both desloratadine alone and desloratadine plus montelukast administered once daily yield improvements with respect to the baseline assessment, regarding the suppression of the dermographometer challenge test papule and clin. improvement of urticaria. However, the combination of desloratadine and montelukast was shown to be more efficacious and may therefore be proposed in patients with DPU, in order to avoid corticosteroid therapy. .